Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Kite Pharma (KITE) downgraded to Hold from Buy at Stifel with analyst Thomas Shrader citing valuation. 2. Nutanix (NTNX) downgraded to Underweight at Morgan Stanley with analyst Katy Huberty saying she expects weaker results to continue given a more crowded market, slower OEM growth, fewer deals, and rising DRAM costs, among other reasons. 3. Snap (SNAP) downgraded to Underweight from Neutral at Atlantic Equities with analyst James Cordwell citing premium valuation and maintained its $14 price target. Cordwell believes the current multiple is unsustainable given unproven monetization potential, challenges re-accelerating user growth, and structurally lower profitability. 4. Kroger (KR) downgraded to Buy from Conviction Buy at Goldman with analyst Stephen Tanal saying the fourth quarter update demonstrated Kroger's competitive edge as eroded a bit and suggest the company is losing share to key competitor Wal-Mart (WMT), which accelerated its grocery business in Q4. 5. Southern Company (SO) downgraded to Hold from Buy at Argus with analyst Katelyn Bayone citing significant delays and cost overruns at its Kemper County plant. The analyst said Southern has now pushed back the commercial operation of the Kemper "clean-coal" plant to mid-March. The plant was originally scheduled to open in 2013, though the opening has been repeatedly pushed back. Bayone said the plant's economic viability has become less certain due to lower-than-expected natural gas prices. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,
click here.